Ranking of Supplements for Muscle Mass in Sarcopenia (After Leucine + Whey Protein)
For older adults with sarcopenia already taking leucine (~3g) and whey protein (20-30g) daily, HMB ranks first with modest evidence for additional benefit, while Velocitol and ursolic acid cannot be recommended due to absence of clinical evidence in this population.
1. HMB (β-Hydroxy-β-methylbutyrate) - FIRST RANK
HMB shows the most evidence but with important caveats about its actual clinical benefit.
Evidence Supporting HMB:
- Most recent high-quality data (2026) shows HMB added to 40g whey protein further enhanced muscle protein synthesis specifically in older women and suppressed muscle protein breakdown in both sexes 1
- A 2023 RCT demonstrated significant improvements in handgrip strength (+4.61 kg), gait speed (+0.11 m/s), and muscle quality (+2.47 kg/kg⁻¹) when HMB was added to resistance training 2
- Meta-analysis (2025) showed beneficial effects on skeletal muscle mass index (SMD=0.32) and handgrip strength (SMD=0.65) in sarcopenia patients 3
Critical Limitations:
- A comprehensive 2026 meta-analysis of 561 participants found NO significant benefit when HMB was combined with resistance training in adults ≥50 years for fat mass, muscle mass, or muscle strength 4
- Another 2022 RCT showed HMB did NOT enhance resistance training effects on muscle quality in older women 5
- The evidence is highly contradictory and heterogeneous
Practical Recommendation:
- Dose: 3g calcium-HMB daily (typically 1.5g twice daily)
- May provide marginal additional benefit in older women or those unable to perform structured resistance training
- Do NOT expect dramatic results - effects are modest at best
- Most beneficial when combined with resistance exercise 6
2. Velocitol (Amylopectin + Chromium Complex) - SECOND RANK (NOT RECOMMENDED)
No clinical evidence exists for Velocitol in older adults with sarcopenia.
- Zero studies identified in sarcopenia populations
- No guideline recommendations
- Theoretical mechanism involves insulin signaling enhancement, but this is unproven in the target population
- Cannot be recommended based on available evidence
3. Ursolic Acid - THIRD RANK (NOT RECOMMENDED)
No clinical evidence exists for ursolic acid in older adults with sarcopenia.
- Zero studies identified in sarcopenia populations
- No guideline recommendations
- Preclinical data exists but has not translated to human trials in this population
- Cannot be recommended based on available evidence
Key Clinical Considerations
What Actually Works (Per Guidelines):
The 2025 and 2023 guidelines emphasize that protein intake of 1.0-1.2 g/kg/day distributed as ~0.4 g/kg per meal is the foundation 7, 8. Your patient is already achieving this with leucine + whey protein.
Common Pitfalls:
- Expecting supplements to replace exercise: Resistance training remains the cornerstone - no supplement can substitute for this 7
- Sexual dimorphism: HMB may work better in older women than men 1
- Overestimating benefit: Even when HMB shows statistical significance, the clinical effect sizes are small
- Ignoring whole foods: Guidelines emphasize that protein from whole foods should be prioritized over isolated supplements 7
The Bottom Line Algorithm:
- Ensure adequate total protein (1.0-1.2 g/kg/day) - ✓ Already achieved
- Implement resistance training - This is non-negotiable
- Consider HMB (3g/day) ONLY if:
- Patient is female, OR
- Unable to perform optimal resistance training, OR
- Willing to accept modest/uncertain benefit
- Do NOT use Velocitol or ursolic acid - no evidence
Reality Check:
The evidence for adding ANY supplement beyond adequate protein and leucine is weak and contradictory 4. The 2026 meta-analysis concludes that "HMB supplementation cannot be recommended as a routine adjunct to resistance training" 4. If you choose to trial HMB, set realistic expectations with patients about likely modest benefits at best.